Leaders in Pharmaceutical Business Intelligence (LPBI) Group

8:40 am – 9:30 am   3/27/2015  Better Business Track: Innovative Ways to Fund Your Early-Stage Company @ MassBio Annual Meeting 2015, Cambridge, MA, Sonesta Hotel, 3/26 – 3/27, 2015

Dr. Aviva Lev-Ari will be in attendance on March 26, 2015, 8:00AM to March 27, 2015, 2:00PM

Leaders in Pharmaceutical Business Intelligence are Covering the Event in REALTIME using Social Media

http://pharmaceuticalintelligence.com

Panelists:

• Navroze Alphonse, Managing Member, Crossover Capital Management LLC

1. lack of provider liquidity, assets of small start ups, peers in VC shy away from type of investment in early stage. Significant need on the private side infusion of 5-10 millions, investors advisors, introductions to large finance for next step
2. How deals are structured? 10Milliond market Cap, run by Founder – value extraction from assets, Healthcare value from an assets, Preferred Equity, straight debt, Equity deals are clean, asset to capitalize, Premioum conversion for owners, bring to a point for second round by them selves or by others, examples of Dilution, Exit is the goal,negotiation to participate

• Scott Jordan, Founder, Healthios Capital Markets, LLC – it is an EXCHANGE for Healthcare investment

1. CouwdFunding – Yesterday a monumental day – Access to Capital, on the Exchange – raise small funds from may investors, 65 company, minimum investment, FinTech – AliBank,
2. Technology

• Walter Capone, President & CEO, The Multiple Myeloma Reseach Foundation

1. Foundation was started by a patient in 1998, extend life of patients, blood related cancers, Consortium of comapnies to support Science, first tissue bank, Myeloma Genome, melanoma, clinical trials. Alnology to Apple in 1982 and the innovation of the PC.
2. Big Pharma, Biotech, Academia spin off — how to advance drugs, return to shareholders
3. Foundation invest in ventures small after a breakthrough with FDA,
4. Misssion to cure Cancer
5. Accelerating the process, progress the process of drug development and deminish risks
6. 60 Clinical Trial half in Phase II
7. Advisory Board select investment for accelerations
8. If side effect or adverse – quickly assess
9. validation, estimation of level of success
10. 80% of funds come from Patients and Families – Fidutiary highest, getting money from Patients
11. Pathways fro Mechanism of Action — comparative cohorts to reduce risk, available patients for Trials
12. Foundation curves competitiveness and augments colloberation
13. Women are the majority of officers at the Foundation

• Yuval Cohen, CEO, Corbus Pharmaceuticals

1. Sclarderma, orphan drugs, rare disease, private placement, Large institutions investors, Phase II office of nine
2. Unlock value and reach markets as soon as possible
3. carry private placement – one share and a callable warrant, 20 million of committed funds, public investors:  S1 SHARE REGISTRATION
4. In 60 days 25% large Institution investors, 75% retail
5. return 15 million as return to angels, 80 million trading
6. transperancy
7. FIVE Groups of Angel — Communicate with Angels — protect them, second phase is not favorable for angels, give warrants and bonuses

• Rick Jones, Broadview Ventures

1. take equity position, Family Trust for Cardiovascular development angels
2. more risk than VCs, they do not want involvement till the Asset is in Phase II.
3. Early stage financing, get to next point to raise follow up financing
4. returns – profit, follow up financing is need thus, early stage will get an asset to the second stage Philantropic componenet

Moderator:

• William Whelan, Co-Chair, Life Sciences Practice, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, PC